Accelerated Approval: Oncopeptides' Pepaxto Will Test New Expedited Withdrawal Process

Company’s appeal of the US FDA’s formal request to voluntarily withdraw accelerated approval of the multiple myeloma agent is expected to follow the streamlined procedures created in last year’s omnibus legislation, which would preclude a second advisory committee review of melflufen’s fate.